BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zheng T, Wang A, Hu D, Wang Y. Tumor-targeting templated silica nanoparticles as a dual-drug delivery system for anti-angiogenic ovarian cancer therapy. Exp Ther Med 2017;14:2162-70. [PMID: 28962137 DOI: 10.3892/etm.2017.4777] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Meng L, Ren Q, Meng Q, Zheng Y, He M, Sun S, Ding Z, Li B, Wang H. Trastuzumab modified silica nanoparticles loaded with doxorubicin for targeted and synergic therapy of breast cancer. Artificial Cells, Nanomedicine, and Biotechnology 2018;46:S556-63. [DOI: 10.1080/21691401.2018.1501380] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
2 Fernandes C, Suares D, Yergeri MC. Tumor Microenvironment Targeted Nanotherapy. Front Pharmacol 2018;9:1230. [PMID: 30429787 DOI: 10.3389/fphar.2018.01230] [Cited by in Crossref: 56] [Cited by in F6Publishing: 44] [Article Influence: 14.0] [Reference Citation Analysis]
3 Zhang M, Chen X, Radacsi N. New tricks of old drugs: Repurposing non-chemo drugs and dietary phytochemicals as adjuvants in anti-tumor therapies. J Control Release 2021;329:96-120. [PMID: 33259852 DOI: 10.1016/j.jconrel.2020.11.047] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
4 Li X, Jia X, Niu H. Nanostructured lipid carriers co-delivering lapachone and doxorubicin for overcoming multidrug resistance in breast cancer therapy. Int J Nanomedicine 2018;13:4107-19. [PMID: 30034236 DOI: 10.2147/IJN.S163929] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
5 Salmanoğlu DS, Çetin Uyanikgil EÖ. Metalik nanopartiküllerin hedeflendirilmesi. Ege Tıp Dergisi. [DOI: 10.19161/etd.698596] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Liang Q, Zhou L, Li Y, Liu J, Liu Y. Nano drug delivery system reconstruct tumour vasculature for the tumour vascular normalisation. J Drug Target 2021;:1-12. [PMID: 33960252 DOI: 10.1080/1061186X.2021.1927056] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Fang J, Zhang S, Xue X, Zhu X, Song S, Wang B, Jiang L, Qin M, Liang H, Gao L. Quercetin and doxorubicin co-delivery using mesoporous silica nanoparticles enhance the efficacy of gastric carcinoma chemotherapy. Int J Nanomedicine 2018;13:5113-26. [PMID: 30233175 DOI: 10.2147/IJN.S170862] [Cited by in Crossref: 42] [Cited by in F6Publishing: 12] [Article Influence: 10.5] [Reference Citation Analysis]
8 Gupta S, Pathak Y, Gupta MK, Vyas SP. Nanoscale drug delivery strategies for therapy of ovarian cancer: conventional vs targeted. Artif Cells Nanomed Biotechnol 2019;47:4066-88. [PMID: 31625408 DOI: 10.1080/21691401.2019.1677680] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
9 Sakurai Y, Harashima H. Hyaluronan-modified nanoparticles for tumor-targeting. Expert Opinion on Drug Delivery 2019;16:915-36. [DOI: 10.1080/17425247.2019.1645115] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
10 Liang P, Ballou B, Lv X, Si W, Bruchez MP, Huang W, Dong X. Monotherapy and Combination Therapy Using Anti-Angiogenic Nanoagents to Fight Cancer. Adv Mater 2021;33:e2005155. [PMID: 33684242 DOI: 10.1002/adma.202005155] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 14.0] [Reference Citation Analysis]